干扰素α治疗慢性乙型肝炎过程中外周血树突状细胞亚群的变化及疗效关系

目的观察α干扰素(IFNα)治疗慢性乙型肝炎(CHB)过程中外周血树突状细胞(DCs)亚群的变化及其与临床疗效的关系。方法慢性乙型肝炎患者25例,应用α干扰素治疗24周,随访24周。利用流式细胞技术对患者外周血mDC和pDC的百分比和绝对数进行随访观察。结果治疗有效组13例,无效组12例。IFNα治疗CHB患者24周时HBVDNA阴转率、HBeAg阴转率、抗HBe阳转率分别为35%、40%、10%;48周时分别为40%、33.3%、20%。外周血mDC和pDC的百分比和绝对数在IFNα治疗后均呈下降趋势。其中,治疗有效组患者在治疗前,治疗后12周、24周、48周时mDC和pDC绝对数分别为(16.5±5.51)×106/L、(9.86±5.2)×106/L、(9.20±3.19)×106/L、(10.0±3.64)×106/L和(5.91±2.35)×106/L、(4.25±2.00)×106/L、(3.30±1.55)×106/L、(4.32±1.59)×106/L,分别进行多组间方差分析,均有统计学意义;无效组患者在治疗前,治疗后12周、24周、48周时mDC和pDC绝对数分别为(14.4±6.62)×106/L、(14.0±5.27)×106/L、(10.40±4.6)×106/L、(12.3±5.23)×106/L和(5.10±1.72)×106/L、(4.06±1.67)×106/L、(3.89±1.25)×106/L、(4.06±8.12)×106/L,经统计学处理,均无统计学意义。结论FNα治疗可以获得持续性病毒学及生化学应答。IFNα治疗可导致体内

Clinical profiles of circulating dendritic cell subsets in chronically HBV-infected patients with interferon-alpha treatment

OBJECTIVE: To investigate the changes of circulating dendritic cell (DC) sunsets in chronic hepatitis B patients treated with alpha-interferon and correlation thereof with therapeutic effectiveness. METHODS: Twenty-five patients with chronic hepatitis B. 24 males and 1 females, aged 18 approximately 43, were treated with subcutaneous injection of alpha-interferon for 24 weeks and then followed up for another 24 weeks. Blood routine, liver function, renal function, and serum HBV DNA were examined before treatment, and 12, 24, and 48 weeks after beginning of treatment. Peripheral blood samples were collected to detect the DC subsets by flow cytometry. RESULT: Those patients with complete or partial recovery of alanine transaminase (ALT) and negative seroconversion or decrease of HBV DNA with/without negative seroconversion of HBeAg and HBsAg were grouped as alpha-interferon responders, and those failing to reach the above criteria were grouped as nonresponders. The negative seroconversion rates of HBV DNA and HBeAg, and positive seroconversion rate of anti-HBe were 35%, 40%, and 10 respectively after 24 weeks' treatment and were 40%, 33.3%, and 20% respectively after 48 weeks' treatment. The numbers of myeloid dendritic cells (mDCs) were 16.5 +/- 5.51 x 10(6)/L, 9.86 +/- 5.2 x 10(6)/L, 9.20 +/- 3.19 x 10(6)/L, and 10.0 +/- 3.64 x 10(6)/L respectively in the alpha-interferon responders (P = 0.045); and were 14.41 +/- 6.62 x 10(6)/L, 14.0 +/- 5.27 x 10(6)/L, 10.40 +/- 4.6 x 10(6)/L, and 12.3 +/- 5.23 x 10(6)/L respectively in the non-responders (P = 0.283) before treatment, and after 12, 1 24, and 48 weeks' treatment respectively. The numbers of plasmacytoid dendritic cells (pDCs) were 5.91 +/- 2.35 x 10(6)/L, 4.25 +/- 2.00 x 10(6)/L, 3.30 +/- 1.55 x 10(6)/L, and 4.32 +/- 1.59 x 10(6)/L respectively in the alpha-interferon responders (P = 0.004); and were 5.10 +/- 1.72 x 10(6)/L, 4.06 +/- 1.67 x 10(6)/L, 3.89 +/- 1.25 x 10(6)/L, and 4.06 +/- 8.12 x 10(6)/L respectively in the non-responders before treatment, and after 12, 24, and 48 weeks' treatment respectively ((P = 0.211). CONCLUSION: Effective on CHB, alpha-interferon induces the percentages and numbers of circulating DC subsets, especially in the-interferon responders.